Alex Gallagher

[Int Society of Nephrology @ISNkidneycare]

"…while it remains that there may be a BP independent effect on LVM or PWV from spiro, this is likely to be small. Controlling BP remains the main way of improving patient outcomes. The gain from using ACEi/ARB/MRA should not be at the expense of safety or patient QoL." Dr Ferro

[Int Society of Nephrology @ISNkidneycare]

The dawn of a new era in Lupus nephritis? Use of the novel calcineurin inhibitor voclosporin in the AURORA trial lead to more complete renal response over standard therapy. Check out this trial and more in this month’s GTF.

[Int Society of Nephrology @ISNkidneycare]

Ogata et al. find no benefit to lanthanum carbonate over calcium carbonate in cardiovascular outcomes when managing hyperphosphatemia in hemodialysis patients but the generalisability of these results needs consideration. See the full review in this month’s GTF.

[Int Society of Nephrology @ISNkidneycare]

Bhandari and colleagues have taken an exploratory look at whether iron therapy offers similar functional benefits in CKD as seen in heart failure with their latest trial. Find our review of this paper and more in this month’s edition of the ISN GTF.

[Int Society of Nephrology @ISNkidneycare]

The ISN’s GTF Pick of the Month goes to the AKIKI2 trial for its efforts to define how long is too long to wait in initiation of dialysis for AKI in an ICU setting. See this month’s edition of the GTF for details and more trials from around the globe.

[Alex Gallagher @Alex26791206]

RSC is the place to be @markbro14687254